JOSEPH O'DONOGHUE

Summary

Affiliation: Memorial Sloan-Kettering Cancer Center
Country: USA

Publications

  1. pmc Pilot study of PET imaging of 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer
    Joseph A O'Donoghue
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    EJNMMI Res 3:42. 2013
  2. ncbi request reprint Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy
    Joseph A O'Donoghue
    Memorial Sloan Kettering Cancer Center and Ludwig Institute for Cancer Research, New York, NY 10021, USA
    Cancer Biother Radiopharm 17:435-43. 2002
  3. ncbi request reprint Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent mic
    Joseph A O'Donoghue
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 61:1493-502. 2005
  4. ncbi request reprint Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy
    JOSEPH O'DONOGHUE
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Biother Radiopharm 19:378-87. 2004
  5. pmc Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia
    HyungJoon Cho
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Neoplasia 11:247-59, 2p following 259. 2009
  6. pmc Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging
    Wenli Wang
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Phys Med Biol 54:3083-99. 2009
  7. pmc In vivo characterization of a reporter gene system for imaging hypoxia-induced gene expression
    Sean Carlin
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nucl Med Biol 36:821-31. 2009
  8. pmc Image deconvolution in digital autoradiography: a preliminary study
    Mutian Zhang
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Med Phys 35:522-30. 2008
  9. pmc Image-guided PO2 probe measurements correlated with parametric images derived from 18F-fluoromisonidazole small-animal PET data in rats
    Rachel M Bartlett
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Nucl Med 53:1608-15. 2012
  10. pmc Radiosynthesis of [(131)I]IAZGP via nucleophilic substitution and its biological evaluation as a hypoxia marker - is specific activity a factor influencing hypoxia-mapping ability of a hypoxia marker?
    Makiko Suehiro
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Nucl Med Biol 36:477-87. 2009

Collaborators

Detail Information

Publications12

  1. pmc Pilot study of PET imaging of 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer
    Joseph A O'Donoghue
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    EJNMMI Res 3:42. 2013
    ....
  2. ncbi request reprint Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy
    Joseph A O'Donoghue
    Memorial Sloan Kettering Cancer Center and Ludwig Institute for Cancer Research, New York, NY 10021, USA
    Cancer Biother Radiopharm 17:435-43. 2002
    ..Treatment may be prescribed on the basis of administered activity or absorbed dose. An optimal definition of maximum tolerated dose will enable the clinical benefits of RIT to be maximized...
  3. ncbi request reprint Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent mic
    Joseph A O'Donoghue
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY, USA
    Int J Radiat Oncol Biol Phys 61:1493-502. 2005
    ..To compare two potential positron emission tomography (PET) tracers of tumor hypoxia in an animal model...
  4. ncbi request reprint Relevance of external beam dose-response relationships to kidney toxicity associated with radionuclide therapy
    JOSEPH O'DONOGHUE
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Cancer Biother Radiopharm 19:378-87. 2004
    ..Animal studies have also clarified the dose-dependency of the time to expression of radiation nephropathy and have indicated that radiation nephropathy may be alleviated by pharmacological means...
  5. pmc Noninvasive multimodality imaging of the tumor microenvironment: registered dynamic magnetic resonance imaging and positron emission tomography studies of a preclinical tumor model of tumor hypoxia
    HyungJoon Cho
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Neoplasia 11:247-59, 2p following 259. 2009
    ....
  6. pmc Evaluation of a compartmental model for estimating tumor hypoxia via FMISO dynamic PET imaging
    Wenli Wang
    Memorial Sloan Kettering Cancer Center, 1275 York Avenue, New York, NY 10021, USA
    Phys Med Biol 54:3083-99. 2009
    ....
  7. pmc In vivo characterization of a reporter gene system for imaging hypoxia-induced gene expression
    Sean Carlin
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10021, USA
    Nucl Med Biol 36:821-31. 2009
    ..To characterize a tumor model containing a hypoxia-inducible reporter gene and to demonstrate utility by comparison of reporter gene expression to the uptake and distribution of the hypoxia tracer (18)F-fluoromisonidazole ((18)F-FMISO)...
  8. pmc Image deconvolution in digital autoradiography: a preliminary study
    Mutian Zhang
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    Med Phys 35:522-30. 2008
    ..Digital autoradiograms following deconvolution show improved sharpness and contrast relative to the unprocessed autoradiograms...
  9. pmc Image-guided PO2 probe measurements correlated with parametric images derived from 18F-fluoromisonidazole small-animal PET data in rats
    Rachel M Bartlett
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, New York 10065, USA
    J Nucl Med 53:1608-15. 2012
    ..The objective of this study was to determine whether kinetic analysis of dynamic (18)F-fluoromisonidazole data provides better discrimination of tumor hypoxia than methods based on a simple tissue-to-plasma ratio...
  10. pmc Radiosynthesis of [(131)I]IAZGP via nucleophilic substitution and its biological evaluation as a hypoxia marker - is specific activity a factor influencing hypoxia-mapping ability of a hypoxia marker?
    Makiko Suehiro
    Department of Medical Physics, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    Nucl Med Biol 36:477-87. 2009
    ....
  11. pmc Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer
    Michael J Morris
    Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
    J Clin Oncol 27:2436-42. 2009
    ..To build on this strategy and fully integrate a repetitively dosed bone-seeking radiopharmaceutical into a contemporary chemotherapy regimen, we conducted a phase I study of docetaxel and samarium-153 ((153)Sm) lexidronam...
  12. pmc Preclinical radioimmunotargeting of folate receptor alpha using the monoclonal antibody conjugate DOTA-MORAb-003
    Peter M Smith-Jones
    Nuclear Medicine Service, Department of Radiology, Memorial Sloan Kettering Cancer Center, Box 77, New York, NY 10021, USA
    Nucl Med Biol 35:343-51. 2008
    ..The in vitro and in vivo behavior of the radiolabeled monoclonal antibody MORAb-003 was investigated as a prelude to a clinical trial...